Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H
Department of Pathology, Klinikum Steglitz, Free University, Berlin, FRG.
Blood. 1989 Oct;74(5):1678-89.
The production and characterization of a monoclonal antibody (MoAb) designated Ber-H2, directed against a new epitope of the Ki-1 (CD30) antigen, are described. In comparison with the formerly reported Ki-1 MoAb whose reactivity with Hodgkin and Reed-Sternberg (H-RS) cells in frozen tissue sections is well-documented, the Ber-H2 MoAb showed new, important features: the labeling intensity of the Ber-H2 MoAb was much stronger, and the number of positively labeled cells was higher. Most important, however, was that the Ber-H2 MoAb could be applied in routinely processed, formaldehyde-fixed, paraffin-embedded tissue sections. Therefore, it was possible to investigate an unprecedented number of tumors received as frozen or formaldehyde-fixed material for expression of the CD30 antigen. Beside Hodgkin's disease, the Ber-H2 MoAb labeled a variable number of cells in lymphomatoid papulosis, peripheral T-cell lymphomas, and angoimmunoblastic lymphadenopathy. Among B-cell non-Hodgkin's lymphomas (NHLs), some cases containing large centroblast-like or immunoblast-like cells or displaying plasma-cellular differentiation were positive. This finding was in keeping with the reactivity of the Ber-H2 MoAb with activated B-cell blasts and a subpopulation of plasma cells in paraffin sections of normal lymphoid tissue. The diagnostic value of the Ber-H2 MoAb was most significant for a group of anaplastic large-cell (ALC) lymphomas (formerly frequently referred to as malignant histiocytosis or regressive atypical histiocytosis), of which more than 50 cases could be investigated, owing to applicability in paraffin sections. Although about one third of these ALC lymphomas did not express the leukocyte common (CD45) antigen, they were consistently reactive with the Ber-H2 MoAb in both frozen and paraffin-embedded tissue sections. Using the Ber-H2 MoAb, these Ki-1 lymphomas could be easily distinguished from other nonlymphoid anaplastic large-cell tumors.
本文描述了一种名为Ber-H2的单克隆抗体（MoAb）的制备及其特性，该抗体针对Ki-1（CD30）抗原的一个新表位。与先前报道的Ki-1 MoAb相比，其在冷冻组织切片中与霍奇金和里德-斯特恩伯格（H-RS）细胞的反应性已有充分记录，Ber-H2 MoAb显示出一些新的重要特征：Ber-H2 MoAb的标记强度更强，阳性标记细胞数量更多。然而，最重要的是Ber-H2 MoAb可应用于常规处理的、甲醛固定、石蜡包埋的组织切片。因此，有可能对大量作为冷冻或甲醛固定材料接收的肿瘤进行CD30抗原表达的研究。除霍奇金病外，Ber-H2 MoAb在淋巴瘤样丘疹病、外周T细胞淋巴瘤和血管免疫母细胞性淋巴结病中标记了数量不等的细胞。在B细胞非霍奇金淋巴瘤（NHL）中，一些含有大的中心母细胞样或免疫母细胞样细胞或显示浆细胞分化的病例呈阳性。这一发现与Ber-H2 MoAb在正常淋巴组织石蜡切片中与活化B细胞母细胞和浆细胞亚群的反应性一致。Ber-H2 MoAb的诊断价值对于一组间变性大细胞（ALC）淋巴瘤（以前常称为恶性组织细胞增多症或退行性非典型组织细胞增多症）最为显著，由于其适用于石蜡切片，可对其中50多例病例进行研究。尽管这些ALC淋巴瘤中约三分之一不表达白细胞共同抗原（CD45），但它们在冷冻和石蜡包埋的组织切片中均始终与Ber-H2 MoAb反应。使用Ber-H2 MoAb，这些Ki-1淋巴瘤可轻松与其他非淋巴间变性大细胞肿瘤区分开来。
